Zobrazeno 1 - 10
of 11
pro vyhledávání: '"K R, Flaherty"'
Autor:
R Deterding, L R Young, E M Deboer, D Warburton, S Cunningham, N Schwerk, K R Flaherty, K K Brown, M Dumistracel, E Erhardt, J Bertulis, M Gahlemann, S Stowasser, M Griese
Publikováno v:
12.04 - Rare ILD/DPLD.
Autor:
M Kreuter, T M Maher, K Ichikado, J M Oldham, C Valenzuela, H Mueller, K B Rohr, K R Flaherty
Publikováno v:
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Autor:
D Skowasch, M Strek, R W Hallowell, J Kus, H Nunes, T Suda, S Tomassetti, H Mueller, K B Rohr, K R Flaherty
Publikováno v:
TP28. TP028 APPROACH TO THERAPY IN FIBROSING AND NON-FIBROSING ILD.
Publikováno v:
Journal of Nuclear Cardiology. 27:2003-2010
There is no identified level of FDG uptake in cardiac sarcoidosis (CS) associated with increased risk of arrhythmias, conduction disease, heart failure, or death. We aim to utilize standardized uptake value (SUV) quantitation and localization to iden
Publikováno v:
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 27(6)
There is no identified level of FDG uptake in cardiac sarcoidosis (CS) associated with increased risk of arrhythmias, conduction disease, heart failure, or death. We aim to utilize standardized uptake value (SUV) quantitation and localization to iden
Autor:
Vibeke Strand, Dinesh Khanna, Susanna Proudman, Kevin K. Brown, Nicola Dalbeth, Athol U. Wells, K. R. Flaherty, Eric L. Matteson, Rohit Aggarwal, James R. Seibold, Shikha Mittoo
Publikováno v:
The Journal of Rheumatology. 42:2168-2171
Objective.Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systema
Autor:
Takeshi Johkoh, Hiroyuki Taniguchi, Dong Soon Kim, David J. Lederer, David M. Hansell, Ganesh Raghu, Luca Richeldi, Katerina M. Antoniou, Gisli Jenkins, Juergen Behr, J.L. Myers, Athol U. Wells, Joyce S. Lee, K. R. Flaherty, Christopher J. Ryerson, Cottin, Tamera J. Corte, Harold R. Collard, Fernando J. Martinez, Kevin K. Brown, Toby M. Maher, David A. Lynch, Martin Kolb, Junya Fukuoka, Y. Kondoh, Naftali Kaminski
Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically significant, respiratory deterioration of unidentifiable cause. The objective of this international working group report on acute exacerbation of idiopathic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9501ef8b6035abd7ac77d8769981cacc
http://hdl.handle.net/10044/1/33908
http://hdl.handle.net/10044/1/33908
Autor:
K R, Flaherty, E A, Kazerooni, J L, Curtis, M, Iannettoni, L, Lange, M A, Schork, F J, Martinez
Publikováno v:
Chest. 119(5)
To evaluate selection criteria and duration of benefit for patients undergoing lung volume reduction surgery (LVRS).Eighty-nine consecutive patients with severe emphysema who underwent bilateral LVRS were prospectively followed up for up to 3 years.
Autor:
K R, Flaherty, G B, Toews, J P, Lynch, E A, Kazerooni, B H, Gross, R L, Strawderman, K, Hariharan, A, Flint, F J, Martinez
Publikováno v:
The American journal of medicine. 110(4)
We evaluated the risk and potential benefit of high-dose corticosteroid therapy in patients with idiopathic pulmonary fibrosis.We prospectively studied 41 patients with previously untreated, biopsy-proven idiopathic pulmonary fibrosis. Before treatme
Publikováno v:
Radiologic Diagnosis of Chest Disease ISBN: 9781447111795
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38e8235afce70a55a181e140c90aa2bd
https://doi.org/10.1007/978-1-4471-0693-7_16
https://doi.org/10.1007/978-1-4471-0693-7_16